Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMSPG
Discontinued Product
0854 has been discontinued.
View all Glutamate (Metabotropic) Group II Receptors products.
Description: Group III and group II mGlu antagonist
Chemical Name: (RS)-α-Methyl-4-sulfonophenylglycine
Biological Activity for MSPG
MSPG is a relatively non-selective antagonist of presynaptic mGlu receptors in neonatal rat spinal cord and adult rat cerebrocortical mGlu receptors.
Technical Data for MSPG
| M. Wt | 245.25 |
| Formula | C9H11NO5S |
| Storage | Store at RT |
| CAS Number | 169209-64-7 |
| PubChem ID | 3964410 |
| InChI Key | MVDSFPIEJILRME-UHFFFAOYSA-N |
| Smiles | NC(C)(C(O)=O)C1=CC=C(S(=O)(O)=O)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for MSPG
References for MSPG
References are publications that support the biological activity of the product.
Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71 PMID: 8864696
Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851 PMID: 8532166
Thomas et al (1995) Antagonism of L-AP4- and (1S,3S)-ACPD-induced depression of dorsal root-evoked monosynaptic excitation of neonatal rat motoneurones by the novel antagonists MSPG and MPPG. Br.J.Pharmacol. 114 9P
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group II Receptor Antagonists
Keywords: MSPG, MSPG supplier, Group, III, group, II, mGlur, antagonists, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGluR4, mGluR6, mGluR7, mGluR8, Glutamate, Metabotropic, mGlu2, mGlu3, mGluR2, mGluR3, (Metabotropic), 0854, Tocris Bioscience
1 Citation for MSPG
Citations are publications that use Tocris products. Selected citations for MSPG include:
McMullan et al (2012) Metabotropic glutamate receptors inhibit microglial glutamate release. ASN Neuro 4 PMID: 22770428
Reviews for MSPG
There are currently no reviews for this product. Be the first to review MSPG and earn rewards!
Have you used MSPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.